Mylan Discloses its Previous Acquisition of Worldwide Rights to Commercialize Novartis’ Products for $463M

 Mylan Discloses its Previous Acquisition of Worldwide Rights to Commercialize Novartis’ Products for $463M

Mylan Discloses its Previous Acquisition of Worldwide Rights to Commercialize Novartis’ Products for $463M

Shots:

  •  Mylan reveals its undisclosed agreement signed on 30 July, 2018 for worldwide commercialization rights for Novartis’ global cystic fibrosis products,TOBI Podhaler and TOBI solution
  •  Company also revealed the reason for keeping the deal undisclosed, as the transaction was under pre-closing confidentiality restrictions
  • The focus of the purchase is to enrich its respiratory units in US, EU and in certain worldwide markets. The transaction is expected to be paid in H2’18 with ~ $240M of $463M

Click here to read full press release/ article | Ref: Mylan | Image:  Fortune

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post